Novel therapeutic strategies for targeting fatty acid oxidation in cancer.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic pathways and preclinical pharmacology without primary clinical data or systematic review methodology
PubMed 41219902 · doi:10.1186/s40364-025-00855-2
What was done
This narrative review analyzed the role of fatty acid oxidation (FAO) in cancer metabolic rewiring and tumor immunity. The authors specifically examined mechanistic pathways regulated by mitochondrial rate-limiting enzymes, centering on the carnitine palmitoyltransferase 1 (CPT1) family, and evaluated pharmacological approaches alongside barriers to clinical translation.
What was found
The abstract reports no numerical data, effect sizes, or quantitative metrics. It describes qualitatively that neoplasms depend on FAO for proliferation and bioenergetics, that FAO exerts dual immunomodulatory functions in tumors, and that existing pharmacological strategies targeting CPT1 have failed to achieve an acceptable risk-benefit balance for clinical translation.
Why it matters
Targeting lipid metabolic checkpoints like CPT1 represents a potential therapeutic avenue, but successful translation requires resolving safety and immunomodulatory trade-offs.
Limits
The abstract contains no primary human or animal data, no quantitative metrics, and no systematic search protocol. Findings are based entirely on narrative synthesis of biological mechanisms.
Cited by
- supports Carnitine palmitoyltransferase (CPT) is the rate-limiting enzyme for transporting fatty acids into the mitochondria for beta-oxidation.